BRCA Single Gene denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for brca single gene are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies BRCA Single-Gene Testing as Duplicate Therapy

A duplicate-therapy denial for BRCA single-gene testing typically arises when Aetna's records show that comprehensive hereditary cancer panel testing (e.g., a multi-gene panel) has already been authorized or performed, and the plan's clinical policy treats single-gene testing as redundant. It can also occur when a previous BRCA test was performed under a different claim or provider and the insurer's system flags the new order as a repeat. Understanding the exact basis is essential before appealing — the two scenarios require different documentation strategies.

## Federal Appeal Rights

Under ACA §2719, genetic testing denials on non-grandfathered fully-insured plans are subject to internal appeal and then independent external review by an IRO. ERISA self-funded plans carry equivalent rights under ERISA §503. The external-review window is generally four months from the final internal denial. Expedited review is available if the test result is needed urgently to guide imminent treatment decisions.

## Appeal Process and Timeline

1. Obtain the denial letter specifying which prior test Aetna considers duplicative and why. 2. Verify whether the prior test actually covers the same analytes — a multi-gene panel result is not always equivalent to a dedicated BRCA1/2 single-gene analysis for a specific clinical purpose (e.g., variant confirmation, reflex testing, treatment-selection assay). 3. File the internal appeal with documentation distinguishing this test from the prior one; plans must decide pre-service appeals within 30 days. 4. Escalate to external review if the internal denial is upheld.

## Documentation to Gather

• Prior test report: the actual laboratory result from any previous hereditary cancer testing, with the gene panel scope and variant findings clearly identified.
• Clinical distinction letter from the ordering clinician or genetic counselor: a statement explaining why the current test is not redundant — for example, the prior panel did not include the specific BRCA variant class being assessed, or the current test is required for a different clinical purpose (surgical planning, targeted therapy eligibility, cascade testing in a family member).
• Clinical indication records: oncology or genetic counseling notes establishing the current clinical question this test is intended to answer.
• Ordering context: if this is a reflex or confirmatory test, documentation of the sequence of clinical decision-making that necessitates it.

## Criteria-Mapping Strategy

Pull Aetna's Genetic Testing Clinical Policy Bulletin and identify the definition of "duplicate" testing it applies. Map each element of that definition against the clinical record. If the prior test and the current test serve distinct clinical purposes or cover distinct analytes, document that distinction explicitly — the appeal turns on showing these are not equivalent services.